Physician profile
Timothy A Bratton
NPI 1285675876
$1,318.98
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $334 · 2021: $144 · 2023: $179 · 2024: $174 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.07 | 2019-2020 | |
| Pfizer INC. | $136.98 | 2019-2025 | |
| Amgen INC. | $130.73 | 2019-2023 | Repatha |
| Novo Nordisk INC | $126.03 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $94.35 | 2020-2024 | Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $93.68 | 2019-2021 | |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Idorsia Pharmaceuticals US INC | $36.37 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $34.07 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $29.14 | 2019 | |
| Chiesi USA, INC. | $27.19 | 2019 | |
| Glaxosmithkline, LLC. | $27.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $26.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.78 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.51 | 2020 | |
| Allergan, INC. | $18.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.18 | 2019 | |
| Exact Sciences Corporation | $16.87 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $16.02 | 2019 | |
| Dynavax Technologies Corporation | $15.40 | 2025 | Heplisav-B |
| Eisai INC. | $15.10 | 2020 | |
| Amarin Pharma, INC. | $13.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.